“Independent researchers discovered a “very alarming” and “disturbing” spike in newborn deaths in France coinciding with the rollout of vaccines for infants. This increase, the researchers said, coincides with the introduction of Beyfortus RSV vaccine in French hospitals, which began on Sept. 15, 2023. The drug is offered as a “one-time shot for infants born just before or during the RSV season and for those less than 8 months old before the season starts,” and for some high-risk 8- to 19-month-old infants.”
French researchers and other medical experts warned that no long-term studies have been conducted involving Beyfortus and newborns and that the administration of monoclonal antibodies on this population is unprecedented.
We need long term studies. We need data. Our babies are not guinea pigs.
French Researchers Identify ‘Improbably High Rate of Deaths’ in Newborns Who Received New RSV Shot
The Centers for Disease Control and Prevention (CDC) recommended Beyfortus in August 2023 and included it in the C.D.C.’s Vaccines For Children program,
The New York Times has been pushing it.
I do not trust these new vaccines, increasingly they are using the new technology and you don’t know what you’re getting.
France Raises Alarm over ‘Very Disturbing’ Spike in Sudden Deaths of Babies
By: Hunter Fielding, News Addict, January 5, 2024:
French researchers have raised the alarm over the “abnormal” and “improbably high rate” of sudden deaths among newborn babies in France.
Independent researchers discovered a “very alarming” and “disturbing” spike in newborn deaths in France coinciding with the rollout of vaccines for infants.
French researchers identified possible safety signals in babies coinciding with the rollout of Beyfortus, a recently approved monoclonal antibody treatment for respiratory syncytial virus (RSV) in newborns.
The discovery comes as public health authorities ramp up warnings about the spread of respiratory viruses and step up their promotion of the drug.
In interviews with The Defender, the researchers — French independent scientist and authorHélène Banoun, Ph.D., and French statistician Christine Mackoi — explained that data from France’s National Institute of Statistics and Economic Studies (INSEE) indicates an improbably high rate of deaths of babies between 2 and 6 days old in France during September and October 2023.
INSEE is the authority that compiles official birth and death data in France.
This increase, the researchers said, coincides with the introduction of Beyfortus in French hospitals, which began on Sept. 15, 2023.
In an interview with cardiologist Peter McCullough, M.D., MPH, Banoun said that over 200,000 newborn babies in France have been injected with Beyfortus since that date.
The Centers for Disease Control and Prevention (CDC) recommended Beyfortus in August 2023, while the European Medicines Agency (EMA) authorized the drug in September 2022.
Beyfortus was developed jointly by AstraZeneca and Sanofi.
Keep reading….
Article posted with permission from Pamela Geller











